Key Points
- Director Donald Degolyer sold 17,800 Emergent Biosolutions shares for approximately $126,202 at an average price of $7.09, reducing his direct ownership by 13.72% to 111,921 shares. The transaction was conducted under a pre-arranged Rule 10b5-1 trading plan.
- Emergent reported quarterly earnings of $0.60 per share, exceeding the $0.08-per-share loss analysts expected, while revenue of $234.3 million also surpassed estimates. Despite this performance, the company posted a negative net margin of 22.95%.
- Analyst sentiment remains mixed, with a consensus “Hold” rating and a $10 price target; institutional investors own 78.4% of the company’s stock.
Emergent Biosolutions Inc. (NYSE:EBS - Get Free Report) Director Donald Degolyer sold 17,800 shares of the stock in a transaction dated Wednesday, October 7th. The shares were sold at an average price of $7.09, for a total value of $126,202.00. Following the completion of the transaction, the director directly owned 111,921 shares in the company, valued at $793,519.89. The trade was a 13.72% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Emergent Biosolutions Price Performance
Shares of EBS opened at $7.08 on Thursday. The stock has a market cap of $362.94 million, a P/E ratio of -1.99 and a beta of 2.28. Emergent Biosolutions Inc. has a 1 year low of $4.36 and a 1 year high of $14.06. The stock's 50-day moving average price is $6.09 and its two-hundred day moving average price is $7.47. The company has a current ratio of 5.42, a quick ratio of 2.95 and a debt-to-equity ratio of 1.70.
Emergent Biosolutions (NYSE:EBS - Get Free Report) last released its quarterly earnings data on Wednesday, August 5th. The biopharmaceutical company reported $0.60 earnings per share for the quarter, topping the consensus estimate of ($0.08) by $0.68. The business had revenue of $234.30 million for the quarter, compared to analyst estimates of $177.50 million. Emergent Biosolutions had a negative net margin of 22.95% and a positive return on equity of 16.35%. On average, equities analysts predict that Emergent Biosolutions Inc. will post 0.13 earnings per share for the current year.
Wall Street Analyst Weigh In
Several equities analysts have recently issued reports on EBS shares. Weiss Ratings raised shares of Emergent Biosolutions from a "sell (d-)" rating to a "sell (d)" rating in a report on Friday, August 21st. HC Wainwright reaffirmed a "buy" rating and set a $10.00 price objective on shares of Emergent Biosolutions in a research note on Wednesday, September 9th. JPMorgan Chase & Co. began coverage on Emergent Biosolutions in a report on Friday, August 21st. They set an "underweight" rating on the stock. Finally, Zacks Research raised Emergent Biosolutions to a "hold" rating in a research note on Tuesday, August 11th. Three equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of "Hold" and a consensus target price of $10.00.
Read Our Latest Stock Analysis on Emergent Biosolutions
Institutional Inflows and Outflows
A number of institutional investors have recently bought and sold shares of the stock. Integrated Wealth Concepts LLC acquired a new position in shares of Emergent Biosolutions in the second quarter valued at approximately $29,000. Public Employees Retirement System of Ohio bought a new stake in shares of Emergent Biosolutions during the second quarter worth $36,000. Legal & General Group Plc acquired a new stake in shares of Emergent Biosolutions during the second quarter worth $44,000. Tocqueville Asset Management L.P. acquired a new stake in shares of Emergent Biosolutions during the second quarter worth $93,000. Finally, The Manufacturers Life Insurance Company bought a new stake in Emergent Biosolutions in the 2nd quarter valued at $115,000. Institutional investors own 78.40% of the company's stock.
About Emergent Biosolutions
(
Get Free Report)
Emergent BioSolutions Inc (NYSE:EBS) is a life sciences company focused on developing, manufacturing and supplying medical countermeasures for public health threats, including chemical, biological, radiological and nuclear hazards, as well as infectious diseases. The company serves government agencies, healthcare providers and commercial customers.
Emergent's portfolio has included vaccines, therapeutics and other products used to prevent or treat serious health threats. Its offerings include BioThrax, an anthrax vaccine, and ACAM2000, a smallpox vaccine, along with products such as botulism antitoxin and vaccinia immune globulin.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
